Subgroup analysis of East Asians in RAINBOW: A phase 3 trial of ramucirumab plus paclitaxel for advanced gastric cancer-Reference-Cited by-同舟云学术

Subgroup analysis of East Asians in RAINBOW: A phase 3 trial of ramucirumab plus paclitaxel for advanced gastric cancer

Published:2016-02-26 Issue:3 Volume:31 Page:581-589
ISSN:0815-9319
Container-title:Journal of Gastroenterology and Hepatology
language:en
Short-container-title:Journal of Gastroenterology and Hepatology

Author:

Muro Kei¹,Oh Sang Cheul²,Shimada Yasuhiro³,Lee Keun-Wook⁴,Yen Chia-Jui⁵⁶,Chao Yee⁷⁸,Cho Jae Yong⁹,Cheng Rebecca¹⁰,Carlesi Roberto¹¹,Chandrawansa Kumari¹²,Orlando Mauro¹³,Ohtsu Atsushi¹⁴

Affiliation:

1. Department of Clinical Oncology; Aichi Cancer Center Hospital; Nagoya Japan

2. Division of Oncology and Hematology, Department of Internal Medicine; College of Medicine, Korea University

3. National Cancer Center Hospital; Tokyo

4. Seoul National University Bundang Hospital, Seoul National University College of Medicine; Seongnam Korea

5. Graduate Institute of Clinical Medicine; National Cheng Kung University; Tainan

6. Division of Hematology and Oncology, Department of Internal Medicine; National Cheng Kung University Hospital; Tainan

7. Faculty of Medicine; , National Yang-Ming University; Taipei

8. Department of Oncology; Taipei Veterans General Hospital; Taipei

9. Department of Medical Oncology; Yonsei University College of Medicine, Gangnam Severance Hospital; Seoul

10. Eli Lilly and Company; Taipei Taiwan

11. Eli Lilly and Company, Sesto Fiorentino; Florence Italy

12. Eli Lilly and Company; Bridgewater New Jersey USA

13. Eli Lilly and Company; Buenos Aires Argentina

14. Exploratory Oncology Research & Clinical Trial Center (EPOC); National Cancer Center; Kashiwa Japan

Funder

Eli Lilly and Company

Publisher

Wiley

Subject

Gastroenterology,Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/jgh.13153/fullpdf

Reference20 articles.

1. GLOBOCAN 2012: Estimated Cancer Incidence Stomach cancer: estimated cancer incidence, mortality and prevalence worldwide in 2012 http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx?cancer=stomach/Accessed 25 Nov 2014.

2. Geographic difference in safety and efficacy of systemic chemotherapy for advanced gastric or gastroesophageal carcinoma: a meta-analysis and meta-regression;Hsu;Gastric Cancer,2012

3. The impact of ethnicity on the presentation and prognosis of patients with gastric adenocarcinoma. Results from the National Cancer Data Base;Al-Refaie;Cancer,2008

4. Race and ethnicity correlate with survival in patients with gastric adenocarcinoma;Kim;Ann. Oncol.,2010

5. Gastric cancer: a primer on the epidemiology and biology of the disease and an overview of the medical management of advanced disease;Shah;J. Natl. Compr. Canc. Netw.,2010

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of ramucirumab for gastric or gastro-esophageal junction adenocarcinoma: a systematic review and meta-analysis;European Journal of Clinical Pharmacology;2024-08-05

2. Fruquintinib plus paclitaxel versus placebo plus paclitaxel for gastric or gastroesophageal junction adenocarcinoma: the randomized phase 3 FRUTIGA trial;Nature Medicine;2024-06-01

3. Correlation between Efficacy and Cardiovascular Adverse Events in Patients with Advanced Solid Cancer Who Received VEGF Pathway Inhibitors: Hypertension within the First Eight Weeks is Associated with Favorable Outcomes of Patients Treated with VEGF Pathway Inhibitors;Internal Medicine;2024

4. Clinical progress of anti-angiogenic targeted therapy and combination therapy for gastric cancer;Frontiers in Oncology;2023-06-12

5. Progress and remaining challenges in comprehensive gastric cancer treatment;Holistic Integrative Oncology;2022-04-28